Peter Voser - Roche Holding Non-Executive Director
| ROGN Stock | MXN 4,026 14.40 0.36% |
Director
Mr. Peter R. Voser is no longer a NonExecutive Independent Director at Roche Holding Ltd effective June 30th, 2019. He is Member of the Remuneration Committee at the Company. He started his career in 1982 by joining the Royal Dutch Shell. He held there various finance and business roles in Switzerland, the United Kingdom, Argentina and Chile. In 1997 he became Group Chief Internal Auditor at the company and in 1999 he was appointed Chief Financial Officer of Shell Europe Oil Products. In 2001 he became CFO of the Global Oil Products Business and Member of the Oil Products Executive Committee. Between 2002 and 2004, Mr. Voser acted as CFO and an Executive Committee Member of the Asea Brown Boveri Group of Companies. From 2004 and 2009 he held the position of Chief Financial Officer and an Executive Director of Royal Dutch Shell. Since 2009 he was active as Chief Executive Officer of Royal Dutch Shell and since 2010, he has acted as Director of Catalyst. He studied Business Administration at Zuercher Hochschule fuer angewandte Wissenschaften, ZHAW . since 2011.
| Age | 59 |
| Tenure | 13 years |
| Phone | 41 61 688 11 11 |
| Web | https://www.roche.com |
Roche Holding Management Efficiency
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Fabian Castro | Grupo Sports World | N/A | |
| James Cullen | Prudential Financial | 72 | |
| Arturo Perez | Grupo Sports World | 54 | |
| Carlos Elizondo | Grupo Sports World | 44 | |
| Michele Ashby | McEwen Mining | 59 | |
| David Munoz | Grupo Carso SAB | 89 | |
| Claudio Laporte | Grupo Carso SAB | 85 | |
| Richard Brissenden | McEwen Mining | 70 | |
| Constance Horner | Prudential Financial | 73 | |
| Murry Gerber | United States Steel | 66 | |
| Maria Arnal | Grupo Sports World | N/A | |
| Hector Rivero | Grupo Sports World | N/A | |
| Richard Baudouin | Air Transport Services | 66 | |
| Victor Garcia | Grupo Sports World | N/A | |
| Marco Domit | Grupo Carso SAB | 50 | |
| Juan Simon | Grupo Carso SAB | 76 | |
| Arthur Lichte | Air Transport Services | 64 | |
| Luis MacKissack | Grupo Sports World | 55 | |
| Xavier Berron | Grupo Sports World | N/A | |
| Patricia Dennis | United States Steel | 72 | |
| Patricia Menendez | Grupo Sports World | N/A | |
Management Performance
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 |
Roche Holding AG Leadership Team
Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Schadler, Head Communications | ||
| Osamu Nagayama, Member of the Enlarged Corporate Executive Committee and Presidentident and CEO of Chugai | ||
| Michael Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development | ||
| Bruno Eschli, Head Relations | ||
| Silvia Ayyoubi, Member of the Corporate Executive Committee, Head of Group Human Resources | ||
| Sophie KornowskiBonnet, Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering | ||
| Thomas Schinecker, Chief Diagnostics | ||
| Beatrice Mauro, Non-Executive Director | ||
| Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources | ||
| William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals | ||
| Roland Diggelmann, Member of the Corporate Executive Committee, COO of the Division Roche Diagnostics | ||
| James Sabry, Member of the Enlarged Corporate Executive Committee, Global Head Pharma Partnering | ||
| Gottlieb Keller, Member of the Group Executive Committee, General Counsel, Secretary to the Board of Directors | ||
| Urs Jaisli, Chief Compliance Officer | ||
| Daniel ODay, Member of the Corporate Executive Committee, COO Division Roche Pharmaceuticals | ||
| Claudia Bockstiegel, G Counsel | ||
| DeAnne Julius, Non-Executive Director | ||
| Johannes MD, Head Devel | ||
| Karl Mahler, Head of Investor Relations | ||
| Andre Hoffmann, Non-Executive Vice Chairman of the Board | ||
| John Reed, Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development | ||
| Claudia Dyckerhoff, Non-Executive Director | ||
| Fritz Gerber, Honorary Chairman of the Board | ||
| Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications | ||
| Julie Brown, Non-Executive Director | ||
| Richard Lifton, Non-Executive Director | ||
| Paul Bulcke, Non-Executive Director | ||
| Christoph Franz, Non-Executive Director | ||
| PerOlof Attinger, Secretary to the Corporate Executive Committee, Head CEO Office | ||
| Pascale Schmidt, Chief Officer | ||
| Pius Baschera, Non-Executive Director | ||
| Peter Voser, Non-Executive Director | ||
| Bernard Poussot, Non-Executive Director | ||
| John Bell, Non-Executive Director | ||
| Andreas Oeri, Non-Executive Director | ||
| Alan Hippe, Member of the Corporate Executive Committee, CFO, Information Technology Officer | ||
| William Pao, Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research & Early Development (pRED) | ||
| F Hoffmann, IR Contact Officer | ||
| Severin Schwan, Chairman of the Corporate Executive Committee, CEO, Director | ||
| Anita Hauser, Non-Executive Director | ||
| Michael Heuer, Member of the Corporate Executive Committee, Interim CEO Roche Diagnostics |
Roche Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 5.83 T | |||
| Shares Outstanding | 693.89 M | |||
| Shares Owned By Institutions | 40.30 % | |||
| Price To Earning | 421.29 X | |||
| Price To Book | 9.80 X | |||
| Price To Sales | 79.71 X |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roche Holding AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Roche Stock analysis
When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Stocks Directory Find actively traded stocks across global markets |